### Highlights of This Issue

#### SPECIAL FEATURES

**CCR Translations**

- **323** BAP1tism of a Tumor Suppressor
  
  Scott E. Woodman
  
  *See article p. 408*

**Molecular Pathways**

- **326** Molecular Pathways: Osteoclast-Dependent and Osteoclast-Independent Roles of the RANKL/RANK/OPG Pathway in Tumorigenesis and Metastasis
  
  William C. Dougall

**Perspective**

- **336** New Challenges in Endpoints for Drug Development in Advanced Melanoma
  
  Antoni Ribas, Peter Hersey, Mark R. Middleton, Helen Gogas, Keith T. Flaherty, Vernon K. Sondak, and John M. Kirkwood

**Review**

- **342** Multiple Myeloma Mesenchymal Stem Cells: Characterization, Origin, and Tumor-Promoting Effects
  
  Michaela R. Reagan and Irene M. Ghobrial

#### HUMAN CANCER BIOLOGY

- **350** Molecular Analysis of Colorectal Tumors within a Diverse Patient Cohort at a Single Institution
  
  Brooke E. Sylvester, Dezhenq Huo, Andrey Khramtsov, Jing Zhang, Rana V. Smalling, Sope Olugbile, Blase N. Polite, and Olufunmilayo I. Olopade

- **360** A Noncanonical Flt3ITD/NF-κB Signaling Pathway Represses DAPK1 in Acute Myeloid Leukemia
  
  Rajasubramaniam Shanmugam, Padmaja Gade, Anique Wilson-Weekes, Hamid Sayar, Attaya Suvannasankha, Chirayu Goswami, Lang Li, Sushil Gupta, Angelo A. Cardoso, Tareq Al Baghdadi, Katie J. Sargent, Larry D. Cripe, Dhananjaya V. Kalvakolanu, and H. Scott Boswell

- **370** Punctate LC3B Expression Is a Common Feature of Solid Tumors and Associated with Proliferation, Metastasis, and Poor Outcome
  
  Rossitza Lazova, Robert L. Camp, Vincent Klump, Summar F. Siddiqui, Ravi K. Amaravadi, and John M. Pawelek

- **380** Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways
  
  Hiu-Fung Yuen, Ka-Kui Chan, Claire Grills, James T. Murray, Angela Platt-Higgins, Osama Sharaf Eldin, Ken O’Byrne, Pasi Janne, Dean A. Fennell, Patrick G. Johnston, Philip S. Rudland, and Mohamed El-Tanani

- **392** Serum Interleukin-6, Insulin, and HOMA-IR in Male Individuals with Colorectal Adenoma
  
  Yu Sasaki, Hiroaki Takeda, Takeshi Sato, Tomohiko Oriti, Shoichi Nishie, Ko Nagino, Daisuke Iwano, Takao Yaota, Kazuya Yoshizawa, Hideki Saito, Yasuhiisa Tanaka, and Sumio Kawata

- **400** Lifetime Cancer Risks in Individuals with Germline PTEN Mutations
  
  Min-Han Tan, Jessica L. Mester, Joanne Ngeow, Lisa A. Rybicki, Mohammed S. Orloff, and Charis Eng

### CANCER THERAPY: PRECLINICAL

- **408** Histone Deacetylase Inhibitors Induce Growth Arrest and Differentiation in Uveal Melanoma
  
  Solange Landreville, Olga A. Agapova, Katie A. Matatall, Zachary T. Kneass, Michael D. Onken, Ryan S. Lee, Anne M. Bowcock, and J. William Harbour
  
  *See commentary p. 323*

- **417** Leflunomide Induces Apoptosis in Fludarabine-Resistant and Clinically Refractory CLL Cells
  
  Sascha Dietrich, Oliver H. Kramer, Esther Hahn, Claudia Schäfer, Thomas Giese, Michael Hess, Theresa Tretter, Michael Rieger, Jennifer Hülle, Thorsten Zenz, Anthony D. Ho, Peter Dregger, and Thomas Luft
432  Anti-EGFR Antibody Cetuximab Enhances the Cytolytic Activity of Natural Killer Cells toward Osteosarcoma  

442  Bexarotene via CBP/p300 Induces Suppression of NF-κB–Dependent Cell Growth and Invasion in Thyroid Cancer  
Audrey Cras, Béatrice Politis, Nicole Balitrand, Diane Darsin-Bettinger, Pierre Yves Boelle, Bruno Cassinat, Marie-Elisabeth Toubert, and Christine Chomienne

454  Targeting Tumor-Associated Endothelial Cells: Anti-VEGFR2 Immunoliposomes Mediate Tumor Vessel Disruption and Inhibit Tumor Growth  
Andreas Wicki, Christoph Bachlitz, Annette Orleth, Reto Ritschard, Inke Albrecht, Richard Herrmann, Gerhard Christofori, and Christoph Mamot

465  EpCAM/CD3-Bispecific T-cell Engaging Antibody MT110 Eliminates Primary Human Pancreatic Cancer Stem Cells  
Michele Cioffi, Jorge Dorado, Patrick A. Rueuerle, and Christopher Heeschen

475  CPTH6, a Thiazole Derivative, Induces Histone Hypoacetylation and Apoptosis in Human Leukemia Cells  
Daniela Trisciuoglio, Ylenia Ragazzoni, Andrea Pelosi, Marianna Desideri, Simone Carradori, Chiara Gabellini, Giovanna Maresca, Riccardo Nescatelli, Daniela Secchi, Adriana Bolasco, Bruna Bizzarri, Chiara Cavallere, Iqba D’Agnano, Patrizia Filetici, Lucia Ricci-Vitiani, Maria Giulia Rizzo, and Donatella Del Bufalo

487  Tipping the Noxa/Mcl-1 Balance Overcomes ABT-737 Resistance in Chronic Lymphocytic Leukemia  

499  VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC  
Hailing Lu, Gregory N. Dietsch, Maura-Ann H. Matthews, Yi Yang, Smita Ghanekar, Margaret Inokuma, Maria Suni, Vernon C. Maino, Katherine E. Henderson, James Jeffrey Howbert, Mary L. Disis, and Robert M. Hershberg

IMAGING, DIAGNOSIS, PROGNOSIS

502  Loss of 18q22.3 Involving the Carboxypeptidase of Glutamate-like Gene Is Associated with Poor Prognosis in Resected Pancreatic Cancer  
Jih-Hsiang Lee, Elisa Giovannetti, Jin-Hyeok Hwang, Iacopo Petriini, Quyan Wang, Johannes Voortman, Yonghong Wang, Seth M. Steinberg, Niccola Funel, Paul S. Meltzer, Yisong Wang, and Giuseppe Giaccone

514  MicroRNA Molecular Profiles Associated with Diagnosis, Clinicopathologic Criteria, and Overall Survival in Patients with Resectable Pancreatic Ductal Adenocarcinoma  

526  Association of HER2/ErbB2 Expression and Gene Amplification with Pathologic Features and Prognosis in Esophageal Adenocarcinomas  
Harry H. Yoon, Qian Shi, William R. Sukov, Anne E.Wiktor, Malika Khan, Christopher A. Sattler, Axel Grotthey, Tsung-Teh Wu, Robert B. Diasio, Robert B. Jenkins, and Frank A. Sinicrope

CANCER THERAPY: CLINICAL

538  Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma  
John M. Kirkwood, Lars Bastholt, Caroline Robert, Jeff Sosman, James Larkin, Peter Hersey, Mark Middleton, Mireille Cantarini, Victoria Zazuquina, Karin Kemsley, and Reinhard Dummer
Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
Keith T. Flaherty, Patricia M. LoRusso, Angela DeMichele, Vandana G. Abramson, Rachel Courtney, Sophia S. Randolph, M. Naveed Shaik, Keith D. Wilner, Peter J. O'Dwyer, and Gary K. Schwartz

A Genome-Wide Association Study of Overall Survival in Pancreatic Cancer Patients Treated with Gemcitabine in CALGB 80303

Genetic Variations in Epigenetic Genes Are Predictors of Recurrence in Stage I or II Non–Small Cell Lung Cancer Patients
Klaus W. Wagner, Yuanqing Ye, Jie Lin, Ara A. Vaporciyan, Jack A. Roth, and Xifeng Wu

ABOUT THE COVER

Although antiangiogenic therapies are effective and comparatively safe treatments against human cancer, renal toxicity is one of the major concerns. Anti-VEGFR2 immunoliposomes loaded with a chemotherapeutic drug showed marked antitumor activity in various tumor models. Importantly, no long-term renal side effects were evident with this therapy. This image shows a section of mouse kidneys 18 months after repeated injection of anti-VEGFR2 immunoliposomes loaded with doxorubicin. For details, see the article by Wicki and colleagues on page 454 of this issue.
Clinical Cancer Research

18 (2)


Updated version  Access the most recent version of this article at: http://clincancerres.aacrjournals.org/content/18/2

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.
Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.